Jan Christensen - PolyPeptide Group Ex Officer
Insider
Jan Christensen is Ex Officer of PolyPeptide Group AG
| Age | 62 |
| Phone | 41 41 723 20 34 |
| Web | https://www.polypeptide.com |
PolyPeptide Group Management Efficiency
The company has return on total asset (ROA) of 0.0467 % which means that it generated a profit of $0.0467 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0809 %, meaning that it generated $0.0809 on every $100 dollars invested by stockholders. PolyPeptide Group's management efficiency ratios could be used to measure how well PolyPeptide Group manages its routine affairs as well as how well it operates its assets and liabilities.PolyPeptide Group AG has accumulated 14.95 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. PolyPeptide Group has a current ratio of 2.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PolyPeptide Group until it has trouble settling it off, either with new capital or with free cash flow. So, PolyPeptide Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PolyPeptide Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PolyPeptide to invest in growth at high rates of return. When we think about PolyPeptide Group's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Fabian Chiozza | VAT Group AG | 42 | |
| Keighley Peters | Comet Holding AG | 52 | |
| Nicola Rotondo | Comet Holding AG | N/A | |
| M Zickar | VAT Group AG | N/A | |
| U Gantner | VAT Group AG | N/A | |
| Daniel Nieper | Siegfried Holding | N/A | |
| Elisabeth Pataki | Comet Holding AG | 42 | |
| Andr Muller | Idorsia | 60 | |
| Jurgen Roos | Siegfried Holding | 55 | |
| Michael Suter | Bachem Holding AG | N/A | |
| Arnoud Middel | Siegfried Holding | 52 | |
| Julien LLM | Idorsia | 44 | |
| Markus Riederer | Idorsia | 61 | |
| Luigi Cornacchia | Comet Holding AG | N/A | |
| Dionys Ven | Comet Holding AG | 55 | |
| V Valentin | VAT Group AG | N/A | |
| Michael Allison | VAT Group AG | 61 | |
| Enno Schweinberger | Siegfried Holding | N/A | |
| Christoph Boss | Idorsia | 54 | |
| JeanMarc Fellay | Bachem Holding AG | N/A | |
| Ines Najorka | Comet Holding AG | N/A | |
Management Performance
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 |
PolyPeptide Group Leadership Team
Elected by the shareholders, the PolyPeptide Group's board of directors comprises two types of representatives: PolyPeptide Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PolyPeptide. The board's role is to monitor PolyPeptide Group's management team and ensure that shareholders' interests are well served. PolyPeptide Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PolyPeptide Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Miller, Chief Officer | ||
| Daniel Lasanow, Director Operations | ||
| Michael Staheli, Head Communications | ||
| Jan Christensen, Ex Officer | ||
| Neil Thompson, Director Marketing | ||
| Monika Casanova, Chief Officer | ||
| Raymond Vre, Chief Officer | ||
| Christina Vecchio, Gen Sec |
PolyPeptide Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PolyPeptide Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 755.81 M | |||
| Shares Outstanding | 33.12 M | |||
| Shares Owned By Insiders | 59.60 % | |||
| Shares Owned By Institutions | 29.93 % | |||
| Price To Book | 1.90 X | |||
| Price To Sales | 2.82 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.